免疫抑制剤治療薬モニタリング:医療機器パイプライン分析

◆英語タイトル:Immunosuppressant Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019
◆商品コード:GDT20FB0210
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:95
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD8,000 ⇒換算¥848,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD12,000 ⇒換算¥1,272,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Immunosuppressant Therapeutic Drug Monitoring – Medical Devices Pipeline Assessment, 2019
Summary

GlobalData’s Medical Devices sector report, “Immunosuppressant Therapeutic Drug Monitoring – Medical Devices Pipeline Assessment, 2019″ provides an overview of Immunosuppressant Therapeutic Drug Monitoring currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunosuppressant Therapeutic Drug Monitoring pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Immunosuppressant Therapeutic Drug Monitoring under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Immunosuppressant Therapeutic Drug Monitoring and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Immunosuppressant Therapeutic Drug Monitoring under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

Table of Contents
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Immunosuppressant Therapeutic Drug Monitoring Overview 7
3 Products under Development 8
3.1 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Stage of Development 8
3.2 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Territory 9
3.3 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Regulatory Path 10
3.4 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Estimated Approval Date 11
4 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products under Development by Companies 12
4.1 Immunosuppressant Therapeutic Drug Monitoring Companies – Pipeline Products by Stage of Development 12
4.2 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Stage of Development 13
5 Immunosuppressant Therapeutic Drug Monitoring Companies and Product Overview 15
5.1 Abbott Diagnostics Company Overview 15
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 15
5.2 BIOHOPE Scientific SL Company Overview 16
5.2.1 BIOHOPE Scientific SL Pipeline Products & Ongoing Clinical Trials Overview 16
5.3 Laboratory Corp of America Holdings Company Overview 17
5.3.1 Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 17
5.4 Ortho-Clinical Diagnostics Inc Company Overview 18
5.4.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 18
5.5 Progenika Biopharma SA Company Overview 22
5.5.1 Progenika Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview 22
5.6 Roche Diagnostics International Ltd Company Overview 23
5.6.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
5.7 Siemens Healthcare Diagnostics Inc Company Overview 43
5.7.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 43
6 Immunosuppressant Therapeutic Drug Monitoring- Recent Developments 49
6.1 Nov 05, 2019: Thermo Fisher Scientific highlights expanded pharma services capabilities during CPhI 49
6.2 Oct 29, 2019: Waters reports third quarter 2019 financial results 50
6.3 Oct 23, 2019: Thermo Fisher Scientific reports third quarter 2019 results 51
6.4 Sep 24, 2019: Theradiag announces improved results for H1 2019 53
6.5 Sep 19, 2019: SenzaGen presents a new commercial organization and a new financial target 56
6.6 Sep 11, 2019: Mark Beaudouin to retire as Waters General Counsel; Company promotes Keeley Aleman 57
6.7 Sep 05, 2019: Thermo Fisher Scientific elects New Director to Board 57
6.8 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 58
6.9 Aug 28, 2019: Waters names Jonathan M. Pratt as President of TA Instruments 58
6.10 Aug 06, 2019: Aurinia reports second quarter 2019 financial results and operational highlights 59
7 Appendix 92
7.1 Methodology 92
7.2 About GlobalData 95
7.3 Contact Us 95
7.4 Disclaimer 95

List of Tables
Table 1: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 9
Table 2: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Territory 10
Table 3: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path 11
Table 4: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date 12
Table 5: Immunosuppressant Therapeutic Drug Monitoring Companies - Pipeline Products by Stage of Development 13
Table 6: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 14
Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 17
Table 8: Alinity i Assay - Methotrexate - Product Status 17
Table 9: Alinity i Assay - Methotrexate - Product Description 17
Table 10: BIOHOPE Scientific SL Pipeline Products & Ongoing Clinical Trials Overview 18
Table 11: Immunobiogram - Renal Transplantation - Product Status 18
Table 12: Immunobiogram - Renal Transplantation - Product Description 18
Table 13: Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 19
Table 14: DoseASSURE RTX Assay - Product Status 19
Table 15: DoseASSURE RTX Assay - Product Description 19
Table 16: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 21
Table 17: VITROS XT 7600 Integrated System - Cedia Cyclosporine Assay - Product Status 21
Table 18: VITROS XT 7600 Integrated System - Cedia Cyclosporine Assay - Product Description 21
Table 19: VITROS XT 7600 Integrated System - Cedia Mycophenolic Acid Assay - Product Status 22
Table 20: VITROS XT 7600 Integrated System - Cedia Mycophenolic Acid Assay - Product Description 22
Table 21: VITROS XT 7600 Integrated System - Methotrexate Assay - Product Status 22
Table 22: VITROS XT 7600 Integrated System - Methotrexate Assay - Product Description 24
Table 23: VITROS XT 7600 Integrated System - QMS Everolimus Assay - Product Status 24
Table 24: VITROS XT 7600 Integrated System - QMS Everolimus Assay - Product Description 24
Table 25: VITROS XT 7600 Integrated System - QMS Tacrolimus Assay - Product Status 25
Table 26: VITROS XT 7600 Integrated System - QMS Tacrolimus Assay - Product Description 25
Table 27: Progenika Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview 26
Table 28: Promonitor - Autoimmune And Inflammation - Product Status 26
Table 29: Promonitor - Autoimmune And Inflammation - Product Description 26
Table 30: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
Table 31: Cobas - Cyclosporin A Assay - Product Status 30
Table 32: Cobas - Cyclosporin A Assay - Product Description 30
Table 33: Cobas - Everolimus Assay - Product Status 31
Table 34: Cobas - Everolimus Assay - Product Description 31
Table 35: Cobas 4000 Analyzer Series With e 411 Module - Cyclosporine Assay - Product Status 31
Table 36: Cobas 4000 Analyzer Series With e 411 Module - Cyclosporine Assay - Product Description 32
Table 37: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Status 32
Table 38: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Description 32
Table 39: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Status 33
Table 40: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Description 33
Table 41: Cobas 6000 Analyzer Series With c 501 Module - Cyclosporine Assay - Product Status 33
Table 42: Cobas 6000 Analyzer Series With c 501 Module - Cyclosporine Assay - Product Description 33
Table 43: Cobas 6000 Analyzer Series With c 501 Module - Everolimus Assay - Product Status 34
Table 44: Cobas 6000 Analyzer Series With c 501 Module - Everolimus Assay - Product Description 34
Table 45: Cobas 6000 Analyzer Series With c 501 Module - Sirolimus Assay - Product Status 34
Table 46: Cobas 6000 Analyzer Series With c 501 Module - Sirolimus Assay - Product Description 35
Table 47: Cobas 6000 Analyzer Series With c 501 Module - Tacrolimus Assay - Product Status 35
Table 48: Cobas 6000 Analyzer Series With c 501 Module - Tacrolimus Assay - Product Description 35
Table 49: Cobas 6000 Analyzer Series With e 601 Module - Cyclosporine Assay - Product Status 35
Table 50: Cobas 6000 Analyzer Series With e 601 Module - Cyclosporine Assay - Product Description 36
Table 51: Cobas 6000 Analyzer Series With e 601 Module - Everolimus Assay - Product Status 36
Table 52: Cobas 6000 Analyzer Series With e 601 Module - Everolimus Assay - Product Description 36
Table 53: Cobas 6000 Analyzer Series With e 601 Module - Sirolimus Assay - Product Status 37
Table 54: Cobas 6000 Analyzer Series With e 601 Module - Sirolimus Assay - Product Description 38
Table 55: Cobas 6000 Analyzer Series With e 601 Module - Tacrolimus Assay - Product Status 38
Table 56: Cobas 6000 Analyzer Series With e 601 Module - Tacrolimus Assay - Product Description 38
Table 57: Cobas 8000 Analyzer Series With c 502 Module - Cyclosporine Assay - Product Status 38
Table 58: Cobas 8000 Analyzer Series With c 502 Module - Cyclosporine Assay - Product Description 39
Table 59: Cobas 8000 Analyzer Series With c 502 Module - Everolimus Assay - Product Status 39
Table 60: Cobas 8000 Analyzer Series With c 502 Module - Everolimus Assay - Product Description 39
Table 61: Cobas 8000 Analyzer Series With c 502 Module - Sirolimus Assay - Product Status 40

List of Figures
Figure 1: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 8
Figure 2: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Territory 9
Figure 3: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path 10
Figure 4: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date 11

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[免疫抑制剤治療薬モニタリング:医療機器パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆